AU704160B2 - Freeze-dried ondansetron compositions - Google Patents

Freeze-dried ondansetron compositions Download PDF

Info

Publication number
AU704160B2
AU704160B2 AU41739/96A AU4173996A AU704160B2 AU 704160 B2 AU704160 B2 AU 704160B2 AU 41739/96 A AU41739/96 A AU 41739/96A AU 4173996 A AU4173996 A AU 4173996A AU 704160 B2 AU704160 B2 AU 704160B2
Authority
AU
Australia
Prior art keywords
ondansetron
freeze
free base
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU41739/96A
Other languages
English (en)
Other versions
AU4173996A (en
Inventor
Ian Keith Winterborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aspen Global Inc
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU704160(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of AU4173996A publication Critical patent/AU4173996A/en
Application granted granted Critical
Publication of AU704160B2 publication Critical patent/AU704160B2/en
Assigned to ASPEN GLOBAL INCORPORATED reassignment ASPEN GLOBAL INCORPORATED Alteration of Name(s) in Register under S187 Assignors: GLAXO WELLCOME INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fertilizers (AREA)
AU41739/96A 1994-11-22 1995-11-20 Freeze-dried ondansetron compositions Expired AU704160B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions
GB9423511 1994-11-22
PCT/EP1995/004550 WO1996015785A1 (en) 1994-11-22 1995-11-20 Freeze-dried ondansetron compositions

Publications (2)

Publication Number Publication Date
AU4173996A AU4173996A (en) 1996-06-17
AU704160B2 true AU704160B2 (en) 1999-04-15

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41739/96A Expired AU704160B2 (en) 1994-11-22 1995-11-20 Freeze-dried ondansetron compositions

Country Status (30)

Country Link
US (2) US5955488A (enExample)
EP (1) EP0793495B1 (enExample)
JP (1) JP3001264B2 (enExample)
KR (1) KR970706814A (enExample)
CN (1) CN1080118C (enExample)
AT (1) ATE193444T1 (enExample)
AU (1) AU704160B2 (enExample)
BE (1) BE1010250A3 (enExample)
BR (1) BR9509808A (enExample)
CY (1) CY2166B1 (enExample)
CZ (1) CZ285250B6 (enExample)
DE (1) DE69517332T2 (enExample)
DK (1) DK0793495T3 (enExample)
ES (1) ES2147309T3 (enExample)
FI (1) FI119355B (enExample)
FR (1) FR2727016B1 (enExample)
GB (2) GB9423511D0 (enExample)
GR (1) GR3033937T3 (enExample)
HU (1) HU226891B1 (enExample)
IL (1) IL116084A (enExample)
IT (1) IT1282352B1 (enExample)
MX (1) MX9703735A (enExample)
NO (1) NO306893B1 (enExample)
NZ (1) NZ296982A (enExample)
PL (1) PL181179B1 (enExample)
PT (1) PT793495E (enExample)
RU (1) RU2159614C2 (enExample)
TW (1) TW398976B (enExample)
WO (1) WO1996015785A1 (enExample)
ZA (1) ZA959821B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
ES2293875T3 (es) * 1997-10-01 2008-04-01 Novadel Pharma Inc. Aerosol bucal no polar.
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
RU2162847C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона и его фармацевтически приемлемых солей
CN1498216A (zh) * 2000-10-30 2004-05-19 ������ҩ��ҵ���޹�˾ 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
DE60314400T2 (de) * 2002-04-29 2008-02-07 Teva Gyogyszergyar Zartköruen Muködo Reszvenytarsasag Verfahren zur herstellung von 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-on
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
HRP20041136A2 (en) * 2002-04-30 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Novel crystal forms of ondansetron, processes fortheir preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1678139B1 (en) * 2003-10-10 2011-08-31 Synhton B.V. Solid-state montelukast
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
CA2567720A1 (en) * 2004-05-24 2005-12-08 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP1919923A1 (en) * 2005-08-17 2008-05-14 Synthon B.V. A process for making olanzapine form i
AR056815A1 (es) * 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101432267A (zh) * 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
ES2325339T3 (es) * 2006-10-24 2009-09-01 Helsinn Healthcare S.A. Capsulas blandas que comprenden hidrocloruro de palonosetron que tienen una estabilidad y una biodisponibilidad mejoradas.
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
RU2363463C1 (ru) * 2007-11-14 2009-08-10 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства Лекарственное средство
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
RU2608458C2 (ru) * 2009-05-20 2017-01-18 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Антагонисты серотониновых 5-нт3-рецепторов для применения при лечении вестибулярных нарушений с повреждениями
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
ES2975016T3 (es) 2016-04-14 2024-07-02 Sensorion (+)-Azasetrón para uso en el tratamiento de trastornos del oído

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084705B1 (en) * 1981-12-11 1987-01-14 JOHN WYETH & BROTHER LIMITED Process for preparing solid shaped articles
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
EP0450757A3 (en) * 1990-02-22 1993-09-15 Glaxo Group Limited Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
FI972167L (fi) 1997-05-21
FI119355B (fi) 2008-10-31
HU226891B1 (en) 2010-01-28
HK1009591A1 (en) 1999-06-04
PL181179B1 (pl) 2001-06-29
TW398976B (en) 2000-07-21
JP3001264B2 (ja) 2000-01-24
CZ154997A3 (en) 1997-10-15
EP0793495B1 (en) 2000-05-31
US5955488A (en) 1999-09-21
KR970706814A (ko) 1997-12-01
EP0793495A1 (en) 1997-09-10
CZ285250B6 (cs) 1999-06-16
PL320295A1 (en) 1997-09-15
WO1996015785A1 (en) 1996-05-30
GB2295318A (en) 1996-05-29
GB9423511D0 (en) 1995-01-11
DK0793495T3 (da) 2000-10-09
CY2166B1 (en) 2002-08-23
NO972325D0 (no) 1997-05-21
JPH10508864A (ja) 1998-09-02
IT1282352B1 (it) 1998-03-20
FR2727016A1 (fr) 1996-05-24
RU2159614C2 (ru) 2000-11-27
PT793495E (pt) 2000-10-31
IL116084A (en) 2000-01-31
GB9523667D0 (en) 1996-01-24
US6063802A (en) 2000-05-16
NO306893B1 (no) 2000-01-10
FI972167A0 (fi) 1997-05-21
ES2147309T3 (es) 2000-09-01
NZ296982A (en) 1998-06-26
NO972325L (no) 1997-05-22
CN1080118C (zh) 2002-03-06
IL116084A0 (en) 1996-01-31
BR9509808A (pt) 1997-10-21
HUT77886A (hu) 1998-09-28
GB2295318B (en) 1998-10-28
DE69517332T2 (de) 2000-11-30
AU4173996A (en) 1996-06-17
ZA959821B (en) 1996-07-31
CN1171741A (zh) 1998-01-28
ITRM950762A1 (it) 1997-05-20
MX9703735A (es) 1998-07-31
ITRM950762A0 (enExample) 1995-11-20
DE69517332D1 (de) 2000-07-06
BE1010250A3 (fr) 1998-04-07
FR2727016B1 (fr) 1998-04-03
GR3033937T3 (en) 2000-11-30
ATE193444T1 (de) 2000-06-15

Similar Documents

Publication Publication Date Title
AU704160B2 (en) Freeze-dried ondansetron compositions
AU703932B2 (en) Oral compositions containing ondansetron
US20050084530A1 (en) Rapid acting freeze dried oral pharmaceutical composition for treating migraine
EP0788789A1 (en) Ranitidine compositions and their use for the treatment of minor gastrointestinal disorders associated with excess acid secretion
UA51615C2 (uk) Застосування сполуки, що має капа опіатагоністичну активність та спосіб лікування
CA2205600C (en) Freeze-dried ondansetron compositions
JPH01316319A (ja) 医薬
MXPA97003734A (en) Oral compositions containing ondanset